In 2016, the FDA broadened the approval of the Cobas test (Roche) to be used not only in tissue sections but also as the first liquid biopsy assay for treatment selection to identify specific EGFR mutations in cfDNA of advanced NSCLC patients [Table 4][29]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.